About the Authors

Kerri Burgess

Affiliation Endocrinology and Metabolism Division, Department of Medicine, University of Rochester, Rochester, New York, United States of America

Tianshun Xu

Affiliation Muscle Metabolism DPU and Platform Technology and Science, GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina, United States of America

Roger Brown

Affiliation Muscle Metabolism DPU and Platform Technology and Science, GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina, United States of America

Bajin Han

Affiliation Muscle Metabolism DPU and Platform Technology and Science, GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina, United States of America

Stephen Welle

stephen_welle@urmc.rochester.edu

Affiliation Endocrinology and Metabolism Division, Department of Medicine, University of Rochester, Rochester, New York, United States of America

Competing Interests

GlaxoSmithKline has a potential commercial interest in the metabolic effects of reducing myostatin activity. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: TX RB BH SW. Performed the experiments: KB SW. Analyzed the data: KB RB SW. Contributed reagents/materials/analysis tools: TX RB BH SW. Wrote the paper: RB SW.